Earlier today, Allergan plc announced it has filed the de novo application for the Oculeve Intranasal Tear Neurostimulator device with the U.S. Food and Drug Administration (FDA).
The Oculeve is reportedly a handheld stimulator used to temporarily increase tear production in patients with dry eye disease due to decreased tear production. The FDA filing comes after Allergan announced two pivotal trials of the Oculeve had met their effectiveness endpoints.
Click here to read the full press release.